New Way Of Controlling Cholesterol May Help Treat Alzheimer's

"We found that this way of reducing cholesterol levels in the brains of living animals both decreased amyloid deposition and improved learning," says the study leader Dora Kovacs, PhD, director of the Neurobiology of Disease Laboratory in the Genetics and Aging Research Unit of MassGeneral Institute for Neurodegenerative Disorders. "As far as we know, this is the first study of cholesterol metabolism's impact on amyloid levels that included cognitive testing."

Researchers have been investigating a potential relationship between cholesterol metabolism and Alzheimer's since it was found that a particular variant of the gene for a protein called apoE significantly increased risk of the disease. Since the apoE protein transports cholesterol, that discovery suggested that disruption of cholesterol handling might cause or worsen the development of the amyloid plaques that characterize Alzheimer's disease. In addition, some epidemiologic studies have suggested that people taking statin drugs to control blood cholesterol have a reduced incidence of Alzheimer's.

In 2001 Kovacs' team showed in cells that the activity of an enzyme called ACAT, which controls whether cholesterol is stored in the cellular membrane or in intracellular droplets, also appears to regulate the formation of amyloid-beta, the protein fragments that make up amyloid plaques. The current study was designed to test that same approach in living animals.

At first, researchers tested whether the ACAT inhibitor used in the 2001 study would affect cholesterol storage in brain cells of mice. Because ACAT inhibitors are metabolized quickly, the researchers used implantable pellets that release the compound in a steady manner and found that the inhibitor significantly reduced the number of cholesterol droplets in brain cells of normal mice.

They then implanted inhibitor pellets in mice with a human gene that leads to amyloid plaque formation. Examination of brain tissue after two months of treatment found that mice receiving the ACAT inhibitor had 90 percent less plaque than did transgenic mice who received placebo pellets. The results were even more dramatic in female mice, who usually develop plaques earlier than males do. Biochemical analysis of mouse brain tissue showed that the inhibitor probably prevents amyloid-beta production, rather than reducing its deposition.

To evaluate the effect of ACAT inhibitor treatment on the mice's cognitive abilities, the researchers had groups of treated and untreated mice swim through a water maze three times a day for four days. The inhibitor did not make a difference for the male mice, which was expected since only female mice would be expected to have enough amyloid in their brains to reduce their ability to find the hidden platform in the water. But those females who received the inhibitor were markedly better at learning the maze than were females with placebo pellets only. In fact, treated female mice learned the maze as well or better than nontransgenic mice did.

While the particular ACAT inhibitor used in this study is not yet appropriate for human trials, Kovacs notes, other ACAT inhibitors are in the process of clinical testing in humans for cardiovascular disease. Her group is now studying one that has been in Phase 3 clinical trials. "It's possible that combining these inhibitors with statin drugs could have even more beneficial effects. If we can duplicate what we found in this animal study with the drug that reached Phase 3 human trials, we could cut ten years from the usual drug development timetable," she says.

Trying to reduce amyloid deposition through cholesterol metabolism may have a special benefit over some other strategies, Kovacs notes. "Many other drugs in development for Alzheimer's target the secretases" – enzymes that cut the larger amyloid precursor protein into smaller fragments, including amyloid-beta. "Because secretases have normal functions, secretase inhibitors have to be tailored to selectively stop amyloid-beta production. Since they do not affect secretases, ACAT inhibitors may have fewer side effects." Kovacs is an assistant professor of Neurology at Harvard Medical School.

###

Co-authors of the Neuron study include first authors Birgit Hutter-Paier, PhD, of JSW Research in Graz, Austria, and Henri Huttunen, PhD, of MGH; Luigi Puglielli, MD, PhD, Doo Yeon Kim, PhD, Robert Moir, PhD, Sarah Domnitz, and Matthow Frosch, MD, PhD, of MGH; and Alexander Hofmeister, and Manfred Windisch, PhD, of JSW Research. The study was supported by grants from the Institute for the Study of Aging, the National Institute for Neurologic Disease and Stroke, and the Alzheimer's Association.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $400 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women's Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.